4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space

The Outpatient and Home Healthcare industry, valued at $390.24 billion in 2023 and projected to grow at a 7.9% CAGR through 2030, is undergoing a significant digital transformation driven by an aging global population, escalating healthcare costs, and increased adoption of telemedicine and AI-powered services. Despite promising near-term prospects indicated by its top-tier Zacks Industry Rank, the sector faces operational challenges including persistent staffing shortages and rising costs due to tariffs on imported medical supplies. Companies like Quest Diagnostics, Encompass Health, DaVita, and The Pennant Group are positioned to capitalize on these evolving market dynamics by embracing technology and expanding service offerings.

Analysis

The Outpatient and Home Healthcare industry is positioned for significant secular growth, with a projected CAGR of 7.9% through 2030, driven by powerful tailwinds including an aging global population, the cost-effectiveness of non-inpatient care, and accelerated adoption of technology like AI and telehealth. The industry's Zacks Rank in the top 19% underscores promising near-term prospects. Despite this positive outlook, the sector faces material headwinds from severe staffing shortages and margin pressure from U.S. tariffs on imported medical supplies. While the industry's stock performance has lagged the S&P 500 over the past year (+6.8% vs +12.1%), its forward P/E of 19.8X is below the broader market and in line with its historical median, suggesting a reasonable valuation. Specific companies are demonstrating distinct strategic execution: The Pennant Group (PNTG) is pursuing aggressive growth through acquisitions with a projected 23.3% revenue increase for 2025, while Encompass Health (EHC) focuses on organic expansion. Quest Diagnostics (DGX) is leveraging its advanced diagnostics portfolio, and DaVita (DVA) shows strong revenue per treatment and an exceptionally high ROE of 176.1%, well above the industry average of 7.9%.

Key Decisions for Investors

• Given the strong secular growth drivers and reasonable industry valuation, investors should consider a selectively bullish approach, focusing on companies best positioned to mitigate operational headwinds like labor shortages and tariffs.
• For growth-oriented portfolios, The Pennant Group (PNTG) warrants attention due to its aggressive acquisition strategy and a sector-leading 2025 revenue growth estimate of 23.3%, though this may carry higher integration risk.
• Investors should closely monitor companies' labor expense ratios and supply chain disclosures, as the ability to manage staffing and absorb tariff-related cost increases will be a key differentiator for profitability.
• While Quest Diagnostics (DGX) and Encompass Health (EHC) offer exposure to established players with solid growth and superior ROE, DaVita (DVA) presents a unique case with its market-leading ROE and positive reimbursement outlook, meriting consideration despite its lower growth profile and 'Hold' rating.